Immix Biopharma, Inc.
IMMX
$2.03
-$0.065-3.10%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.38M | 10.04M | 9.51M | 8.55M | 7.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 22.67M | 23.06M | 20.19M | 19.21M | 16.14M |
| Operating Income | -22.67M | -23.06M | -20.19M | -19.21M | -16.14M |
| Income Before Tax | -21.66M | -22.00M | -19.20M | -18.40M | -15.57M |
| Income Tax Expenses | 41.00K | 38.30K | 34.00K | 30.00K | 26.40K |
| Earnings from Continuing Operations | -21.70 | -22.04 | -19.24 | -18.43 | -15.60 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 85.00K | 150.90K | 214.10K | 223.20K | 169.50K |
| Net Income | -21.61M | -21.89M | -19.02M | -18.21M | -15.43M |
| EBIT | -22.67M | -23.06M | -20.19M | -19.21M | -16.14M |
| EBITDA | -22.64M | -23.05M | -20.18M | -19.20M | -16.14M |
| EPS Basic | -0.78 | -0.85 | -0.84 | -0.93 | -0.88 |
| Normalized Basic EPS | -0.49 | -0.53 | -0.52 | -0.57 | -0.55 |
| EPS Diluted | -0.78 | -0.85 | -0.84 | -0.93 | -0.88 |
| Normalized Diluted EPS | -0.49 | -0.53 | -0.52 | -0.57 | -0.55 |
| Average Basic Shares Outstanding | 111.21M | 103.43M | 92.58M | 78.84M | 69.30M |
| Average Diluted Shares Outstanding | 111.21M | 103.43M | 92.58M | 78.84M | 69.30M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |